Onglyza, the diabetes medication manufactured by AstraZeneca, may be associated with an increased death rate, according to a preliminary review by the Food and Drug Administration (FDA).
While diabetes medications Onglyza and Nesina should include information about the risk of heart failure, the drugs do not increase the risk of cardiovascular death, stroke or heart attack, an advisory committee to FDA said.
Originally, a preliminary review by FDA published last Friday said that Onglyza, (AstraZeneca) may be associated with an increased death rate.
FDA's published the review on its website on Friday, ahead of its April 14 Endocrinologic and Metabolic Drugs Advisory Committee Meeting. The committee will not only discuss the safety of Onglyza, but will also look at diabetes drug Nesina from Takeda Pharmaceutical Co.
However, on Tuesday, the committee did not recommend any restrictions on prescribing the drugs.
Related: Report: Diabetes drives traditional drug trend, specialty trend increases 20%
The review revealed that more than 16,000 patients taking Onglyza in the SAVOR study had an increased risk of hospitalization due to heart failure. FDA said the heart failure risk is valid and that there may a possible increased risk of death, according to a Reuter’s article.
The causes of death were often "multifactorial" and some patients may have had several serious medical conditions prior to death, according to Reuters.
Related: Children's use of antipsychotics may increase risk of diabetes
A similar large study of Nesina, did not raise similar concerns, according to the FDA review.
AstraZeneca said the SAVOR study met the objective of showing that patients taking Onglyza were not at greater risk as measured by a composite benchmark comprising cardiovascular death, non-fatal heart attack and non-fatal ischemic stroke, Reuters reported.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More